Citadel Advisors
CGEM icon

Citadel Advisors’s Cullinan Oncology CGEM Stock Holding History

Citadel Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-163,900
Closed -$1.23M – 12872
2025
Q2 		$1.23M Buy
163,900
+146,000
+816% +$1.17M ﹤0.01% 6635
2025
Q1 		$136K Sell
17,900
-4,300
-19% -$41.3K ﹤0.01% 11028
2024
Q4 		$270K Sell
22,200
-6,200
-22% -$89.1K ﹤0.01% 9866
2024
Q3 		$475K Buy
28,400
+12,500
+79% +$222K ﹤0.01% 8367
2024
Q2 		$277K Buy
15,900
+11,000
+224% +$234K ﹤0.01% 9292
2024
Q1 		$83.5K Sell
4,900
-2,500
-34% -$38.6K ﹤0.01% 11600
2023
Q4 		$75.4K Buy
7,400
+3,400
+85% +$30.1K ﹤0.01% 11294
2023
Q3 		$36.2K Buy
4,000
+1,900
+90% +$19.8K ﹤0.01% 12120
2023
Q2 		$22.6K Buy
2,100
+600
+40% +$6.37K ﹤0.01% 12623
2023
Q1 		$15.3K Buy
1,500
+1,200
+400% +$13.2K ﹤0.01% 13256
2022
Q4 		$3.17K Buy
+300
New +$3.64K ﹤0.01% 14242

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Citadel Advisors's CGEM Position: Q1 2026 in Review

Citadel Advisors increased its Cullinan Oncology (CGEM) stake by 129% in Q1 2026, buying an estimated $1.83M and bringing the position to 252,778 shares worth $3.59M. The position accounts for ﹤0.01% of the portfolio, ranked #4917.

Citadel Advisors first reported a position in CGEM in Q1 2021 and has held it in 21 quarters since. The position peaked at $33.9M in Q2 2024. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Citadel Advisors held 252,778 shares of Cullinan Oncology worth $3.59M as of Q1 2026.
  • Citadel Advisors bought 142,461 Cullinan Oncology shares in Q1 2026, an estimated $1.83M.
  • Cullinan Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4917 holding.
  • Citadel Advisors first reported a position in Cullinan Oncology in Q1 2021 and has held it in 21 quarters since.
  • Citadel Advisors's Cullinan Oncology position peaked at $33.9M in Q2 2024.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.